There has been much buzz recently about Purdue Pharma’s new version of OxyContin, known as OP, which the drug company claims is designed to help discourage misuse and abuse of the medication. But not surprisingly, people hooked on Oxy are already finding ways to get their fix from it, according to the Seattle Weekly. To recap: Purdue continues to reap billions of dollars from sales of the original OxyContin until its patent expires in April 2013, while also profiting from sales of the new OP. Generic competitors are jumping on the bandwagon by lining up their own versions of “tamper-proof” Oxy. And addicts are still addicted and able to feed their habits, all the while lining Big Pharma’s pockets.
Does anyone else see something wrong with this picture?